April 8, 2013 - Children are an at-risk group when using serum calcium lowering medicine Mimpara
In consultation with the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), the Dutch Medicines Evaluation Board (MEB) and the Health Care Inspectorate (IGZ), Amgen would like to inform you of the occurrence of a fatal case with severe hypocalcemia in a pediatric investigational study involving a patient receiving cinacalcet (Mimpara). Cinacalcet is approved only in adults. Prescribers are reminded that since cinacalcet lowers serum calcium, patients should be monitored carefully for the occurrence of hypocalcaemia.
Read more »